

Shun Lu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1836959/publications.pdf>

Version: 2024-02-01

246
papers

19,494
citations

66234

42
h-index

12910

131
g-index

256
all docs

256
docs citations

256
times ranked

14530
citing authors

#	ARTICLE	IF	CITATIONS
1	Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC. <i>Journal of Thoracic Oncology</i> , 2022, 17, 423-433.	0.5	89
2	Pyrotinib in Patients with HER2-Amplified Advanced Non-Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial. <i>Clinical Cancer Research</i> , 2022, 28, 461-467.	3.2	24
3	Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial. <i>Journal of Thoracic Oncology</i> , 2022, 17, 411-422.	0.5	70
4	Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial. <i>Clinical Cancer Research</i> , 2022, 28, 2286-2296.	3.2	14
5	Tagrisso incremental therapy in a case of meningeal metastasis of lung cancer with EGFR mutation: a case report. <i>Translational Lung Cancer Research</i> , 2022, 11, 323-330.	1.3	2
6	Convergent alteration of lung tissue microbiota and tumor cells in lung cancer. <i>IScience</i> , 2022, 25, 103638.	1.9	9
7	OUP accepted manuscript. <i>Oncologist</i> , 2022, 27, 163-e213.	1.9	6
8	Treatment preferences for epidermal growth factor receptor mutation-positive non-small cell lung cancer with brain metastasis: a large-scale survey from Chinese oncologists. <i>Annals of Translational Medicine</i> , 2022, 10, 41-41.	0.7	1
9	Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial. <i>BMC Medicine</i> , 2022, 20, 42.	2.3	26
10	Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2022, 165, 71-81.	0.9	9
11	MARIPOSA: phase 3 study of first-line amivantamab+azertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer. <i>Future Oncology</i> , 2022, 18, 639-647.	1.1	44
12	First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA. <i>International Journal of Clinical Oncology</i> , 2022, 27, 695-706.	1.0	11
13	Indirect comparison of sintilimab and other PD-L1 inhibitors for first-line treatment of non-squamous non-small-cell lung cancer. <i>Future Oncology</i> , 2022, , .	1.1	2
14	Rethinking the Status of Chemotherapy Combined With the Addition of Cytotoxic T-Lymphocyte-Associated Antigen 4 Inhibition and Programmed Death 1 or Programmed Death-Ligand 1 Blockade. <i>Journal of Thoracic Oncology</i> , 2022, 17, 341-344.	0.5	0
15	Examining the Impact of Tislelizumab Added to Chemotherapy on Health-Related Quality-of-Life Outcomes in Previously Untreated Patients With Nonsquamous Non-Small Cell Lung Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2022, 28, 96-104.	1.0	5
16	Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety From a Phase 2 Study in People's Republic of China. <i>Journal of Thoracic Oncology</i> , 2022, 17, 816-826.	0.5	15
17	FGF19 Is Coamplified With CCND1 to Promote Proliferation in Lung Squamous Cell Carcinoma and Their Combined Inhibition Shows Improved Efficacy. <i>Frontiers in Oncology</i> , 2022, 12, 846744.	1.3	3
18	The relationship between different subtypes of KRAS and PD-L1 & tumor mutation burden (TMB) based on next-generation sequencing (NGS) detection in Chinese lung cancer patients. <i>Translational Lung Cancer Research</i> , 2022, 11, 213-223.	1.3	6

#	ARTICLE	IF	CITATIONS
19	Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 1973-1985.	13.9	871
20	Exosomal PD-L1 predicts response with immunotherapy in NSCLC patients. <i>Clinical and Experimental Immunology</i> , 2022, 208, 316-322.	1.1	13
21	AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations. <i>Journal of Clinical Oncology</i> , 2022, 40, 3162-3171.	0.8	76
22	Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patients. <i>Journal of Hematology and Oncology</i> , 2022, 15, 62.	6.9	24
23	Comparison of Efficacy and Safety of Brigatinib in First-Line Treatments for Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Systematic Review and Indirect Treatment Comparison. <i>Journal of Clinical Medicine</i> , 2022, 11, 2963.	1.0	3
24	Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study. <i>Journal of Thoracic Oncology</i> , 2022, 17, 1192-1204.	0.5	7
25	KeyVibe-008: Randomized, phase 3 study of first-line vibostolimab plus pembrolizumab plus etoposide/platinum versus atezolizumab plus EP in extensive-stage small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS8606-TPS8606.	0.8	3
26	Updated analysis of the efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3099-3099.	0.8	16
27	Abstract CT012: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment for resectable (IB-IIIA) non-small cell lung cancer (NSCLC): Event-free survival (EFS) results from the phase 3 CheckMate 816 trial. <i>Cancer Research</i> , 2022, 82, CT012-CT012.	0.4	3
28	Abstract 5537: MGA mutation status affect tumor immunomicroenvironment and predict the effect of immune check point inhibitor: From NSCLC to pan-cancers analysis. <i>Cancer Research</i> , 2022, 82, 5537-5537.	0.4	0
29	Abstract LB512: RATIONALE-304: The association of tumor mutational burden (TMB) with clinical outcomes of tislelizumab (TIS) + chemotherapy (chemo) versus chemo alone as first-line treatment for advanced non-squamous non-small cell lung cancer (nsq-NSCLC). <i>Cancer Research</i> , 2022, 82, LB512-LB512.	0.4	2
30	Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met overexpressing (OE) advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 9016-9016.	0.8	33
31	Abstract CT552: RATIONALE 304: Tislelizumab (TIS) plus chemotherapy versus chemotherapy alone as first-line (1L) treatment for non-squamous (non-sq) NSCLC in patients (pts) aged 65-75 years. <i>Cancer Research</i> , 2022, 82, CT552-CT552.	0.4	0
32	Aumolertinib activity in patients with CNS metastases and EGFR-mutated NSCLC treated in the randomized double-blind phase III trial (AENEAS).. <i>Journal of Clinical Oncology</i> , 2022, 40, 9096-9096.	0.8	6
33	Abstract 5363: The preclinical selectivity and activity of APS03118, a highly selective and potent next-generation RET inhibitor. <i>Cancer Research</i> , 2022, 82, 5363-5363.	0.4	1
34	Abstract CT505: Phase I study of D-1553 to assess safety and efficacy in patients with non-small cell lung cancer (NSCLC) harboring KRASG12C mutation. <i>Cancer Research</i> , 2022, 82, CT505-CT505.	0.4	1
35	Comprehensive analysis of MET mutations in NSCLC patients in a real-world setting. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211124.	1.4	2
36	First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients (pts) with metastatic non-small cell lung cancer (NSCLC): 3-year update from CheckMate 9LA.. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA9026-LBA9026.	0.8	12

#	ARTICLE	IF	CITATIONS
37	SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC).. Journal of Clinical Oncology, 2022, 40, LBA8507-LBA8507.	0.8	46
38	The development of APS03118, a potent next-generation RET inhibitor for treating RET-inhibitor-resistant patients.. Journal of Clinical Oncology, 2022, 40, e15107-e15107.	0.8	4
39	Neoadjuvant nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) versus chemo for resectable (IB—IIIA) non-small cell lung cancer (NSCLC): Association of pathological regression with event-free survival (EFS) in CheckMate 816.. Journal of Clinical Oncology, 2022, 40, LBA8511-LBA8511.	0.8	14
40	Impact of KRAS Mutation Subtypes and Co-Occurring Mutations on Response and Outcome in Advanced NSCLC Patients following First-Line Treatment. Journal of Clinical Medicine, 2022, 11, 4003.	1.0	3
41	Clonal Architecture of <i>EGFR</i> Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641). Clinical Cancer Research, 2021, 27, 704-712.	3.2	20
42	Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078). Lung Cancer, 2021, 152, 7-14.	0.9	40
43	Standardization of pleural effusion-based tumor mutation burden (TMB) estimation using capture-based targeted sequencing. Annals of Translational Medicine, 2021, 9, 140-140.	0.7	4
44	Peripheral CD4+ T cell signatures in predicting the responses to anti-PD-1/PD-L1 monotherapy for Chinese advanced non-small cell lung cancer. Science China Life Sciences, 2021, 64, 1590-1601.	2.3	9
45	Distinct profile of cell-free DNA in malignant pleural effusion of non-small cell lung cancer and its impact on clinical genetic testing. International Journal of Medical Sciences, 2021, 18, 1510-1518.	1.1	13
46	First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncology, The, 2021, 22, 198-211.	5.1	773
47	Fruquintinib with gefitinib as first-line therapy in patients carrying EGFR mutations with advanced non-small cell lung cancer: a single-arm, phase II study. Translational Lung Cancer Research, 2021, 10, 839-854.	1.3	4
48	Docetaxel maintenance therapy versus best supportive care after first-line chemotherapy with different dose docetaxel plus cisplatin for advanced non-small cell lung cancer (TFINE study,) Tj ETQq0 0 0 rgBT /Overlock 10 Jf 50 302 T 338-338.	0.7	3
49	Efficacy and Safety of S-1 Compared With Docetaxel in Elderly Patients With Advanced NSCLC Previously Treated With Platinum-Based Chemotherapy: A Subgroup Analysis of the EAST-LC Trial. JTO Clinical and Research Reports, 2021, 2, 100142.	0.6	1
50	Multigene PCR using both cfDNA and cfRNA in the supernatant of pleural effusion achieves accurate and rapid detection of mutations and fusions of driver genes in patients with advanced NSCLC. Cancer Medicine, 2021, 10, 2286-2292.	1.3	5
51	Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence. Advances in Therapy, 2021, 38, 2038-2053.	1.3	8
52	Hexokinase 2 discerns a novel circulating tumor cell population associated with poor prognosis in lung cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	36
53	Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050). Lung Cancer, 2021, 154, 176-185.	0.9	18
54	Plasma EGFR mutation abundance affects clinical response to first-line EGFR-TKIs in patients with advanced non-small cell lung cancer. Annals of Translational Medicine, 2021, 9, 635-635.	0.7	7

#	ARTICLE	IF	CITATIONS
55	AdvanTIG-302: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus tislelizumab (TIS) versus pembrolizumab (PEM) in programmed death ligand-1 (PD-L1) selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2021, 39, TPS9128-TPS9128.	0.8	6
56	Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-“Small-Cell Lung Cancer. JAMA Oncology, 2021, 7, 709.	3.4	185
57	RATIONALE-307: Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous NSCLC in patients aged ≥ 65.. Journal of Clinical Oncology, 2021, 39, 9102-9102.	0.8	2
58	Serum Metabolite Biomarkers Predictive of Response to PD-1 Blockade Therapy in Non-Small Cell Lung Cancer. Frontiers in Molecular Biosciences, 2021, 8, 678753.	1.6	16
59	Randomized phase III trial of aumolertinib (HS-10296, Au) versus gefitinib (G) as first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and EGFR exon 19 del or L858R mutations (EGFRm).. Journal of Clinical Oncology, 2021, 39, 9013-9013.	0.8	24
60	Chinese advanced fusion-dependent lung cancer patients: Molecular spectrum and treatment options using next generation sequencing—A multicenter study (Yangtze River Delta Lung Cancer Cooperation) Tj ETQq0000 rgBT (Overlock 1	0.8	0
61	Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2021, 39, 8503-8503.	0.8	99
62	Successful treatment of EGFR T790M-mutant non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: a case report and literature review. Annals of Translational Medicine, 2021, 9, 950-950.	0.7	8
63	International consensus on severe lung cancer—the first edition. Translational Lung Cancer Research, 2021, 10, 2633-2666.	1.3	6
64	Durable Response to the Combination of Atezolizumab With Platinum-Based Chemotherapy in an Untreated Non-Smoking Lung Adenocarcinoma Patient With BRAF V600E Mutation: A Case Report. Frontiers in Oncology, 2021, 11, 634920.	1.3	7
65	Mini-patient-derived xenograft assay based on microfluidic technology promises to be an effective tool for screening individualized chemotherapy regimens for advanced non-small cell lung cancer. Cell Biology International, 2021, 45, 1887-1896.	1.4	5
66	Integrated Analysis of Genomic and Immunological Features in Lung Adenocarcinoma With Micropapillary Component. Frontiers in Oncology, 2021, 11, 652193.	1.3	12
67	Abstract CT158: ctDNA analysis in the savolitinib phase II study in Non-Small Cell Lung Cancer (NSCLC) patients (pts) harboring <i>MET exon 14</i> skipping alterations (<i>METex14</i>). Cancer Research, 2021, 81, CT158-CT158.	0.4	4
68	Abstract CT255: Canakinumab as adjuvant therapy in patients with completely resected non-small cell lung cancer: CANOPY-A trial. , 2021, , .		0
69	Safety but Limited Efficacy of Ensartinib in ROS1-Positive NSCLC: A Single-Arm, Multicenter Phase 2 Study. Journal of Thoracic Oncology, 2021, 16, 1959-1963.	0.5	7
70	Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non-“small-cell Lung Cancer: LAURA Trial in Progress. Clinical Lung Cancer, 2021, 22, 371-375.	1.1	44
71	Immunochemotherapy as First-line Treatment for Locally Advanced or Metastatic Squamous Non-“Small Cell Lung Cancers—Reply. JAMA Oncology, 2021, 7, 1580.	3.4	1
72	Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study. Journal of Thoracic Oncology, 2021, 16, 1403-1414.	0.5	26

#	ARTICLE	IF	CITATIONS
73	Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3). <i>Future Oncology</i> , 2021, 17, 4237-4247.	1.1	11
74	The Chinese Thoracic Oncology Group (CTONG) therapeutic option scoring system: a multiple-parameter framework to assess the value of lung cancer treatment options. <i>Translational Lung Cancer Research</i> , 2021, 10, 3594-3607.	1.3	3
75	Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial. <i>BMC Cancer</i> , 2021, 21, 1033.	1.1	9
76	Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study. <i>Cancer Cell</i> , 2021, 39, 1279-1291.e3.	7.7	99
77	Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1512-1522.	0.5	127
78	Knockdown of CDK5 down-regulates PD-L1 via the ubiquitination-proteasome pathway and improves antitumor immunity in lung adenocarcinoma. <i>Translational Oncology</i> , 2021, 14, 101148.	1.7	21
79	Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1154-1164.	5.2	107
80	Propensity score matched analysis for the role of surgery in stage \geq II small cell lung cancer based on the eighth edition of the TNM classification: a population study of the US SEER database and a Chinese hospital. <i>Lung Cancer</i> , 2021, 162, 54-60.	0.9	12
81	A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer. <i>Future Oncology</i> , 2021, 17, 4827-4835.	1.1	1
82	Diverse responses to EGFR-TKIs in patients with concurrent germline and somatic EGFR mutations. <i>Lung Cancer</i> , 2021, 162, 207-209.	0.9	1
83	A multi-omics-based serial deep learning approach to predict clinical outcomes of single-agent anti-PD-1/PD-L1 immunotherapy in advanced stage non-small-cell lung cancer. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 743-756.	0.0	11
84	Predictable Roles of Peripheral IgM Memory B Cells for the Responses to Anti-PD-1 Monotherapy Against Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 759217.	2.2	18
85	NLRP4 negatively regulates type I interferon response and influences the outcome in anti-programmed cell death protein (PD)-1/PD-L1 ligand 1 therapy. <i>Cancer Science</i> , 2021, , .	1.7	7
86	Modelled Economic Analysis for Dacomitinib—A Cost Effectiveness Analysis in Treating Patients With EGFR-Mutation-Positive Non-Small Cell Lung Cancer in China. <i>Frontiers in Oncology</i> , 2021, 11, 564234.	1.3	3
87	Salvage Therapy for Locoregional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 176-189.	0.5	29
88	The effect of PD-L1 categories-directed pembrolizumab plus chemotherapy for newly diagnosed metastatic non-small-cell lung cancer: a cost-effectiveness analysis. <i>Translational Lung Cancer Research</i> , 2020, 9, 1770-1784.	1.3	26
89	A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER. <i>Frontiers in Oncology</i> , 2020, 10, 578756.	1.3	36
90	Immuno-based therapeutic strategies for initial unresectable locally advanced non-small cell lung cancer: a case report. <i>Translational Lung Cancer Research</i> , 2020, 9, 803-806.	1.3	2

#	ARTICLE	IF	CITATIONS
91	PAK5 promotes the cell stemness ability by phosphorylating SOX2 in lung squamous cell carcinomas. <i>Experimental Cell Research</i> , 2020, 395, 112187.	1.2	3
92	Adverse Effects of Combined Tyrosine Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2020, 15, e182-e183.	0.5	0
93	MicroRNA-214-3p inhibits the stem-like properties of lung squamous cell cancer by targeting YAP1. <i>Cancer Cell International</i> , 2020, 20, 413.	1.8	11
94	Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1907-1918.	0.5	85
95	Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 1711-1723.	13.9	1,042
96	Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1119-1136.	0.5	82
97	Circulating tumor DNA clearance predicts prognosis across treatment regimen in a large real-world longitudinally monitored advanced non-small cell lung cancer cohort. <i>Translational Lung Cancer Research</i> , 2020, 9, 269-279.	1.3	64
98	FGFR1 regulates proliferation and metastasis by targeting CCND1 in FGFR1 amplified lung cancer. <i>Cell Adhesion and Migration</i> , 2020, 14, 82-95.	1.1	29
99	Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3-day aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study. <i>Cancer Medicine</i> , 2020, 9, 5134-5142.	1.3	10
100	Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT). <i>Journal of Clinical Oncology</i> , 2020, 38, 1132-1143.	5.2	169
101	A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer – The FALUCA study. <i>Lung Cancer</i> , 2020, 146, 252-262.	0.9	12
102	First-line crizotinib versus platinum-pemetrexed chemotherapy in patients with advanced ROS1-rearranged non-small-cell lung cancer. <i>Cancer Medicine</i> , 2020, 9, 3310-3318.	1.3	24
103	Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. <i>Journal of Thoracic Oncology</i> , 2020, 15, 914-947.	0.5	119
104	IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. <i>Journal of Thoracic Oncology</i> , 2020, 15, 709-740.	0.5	205
105	Enhanced autocrine FGF19/FGFR4 signaling drives the progression of lung squamous cell carcinoma, which responds to mTOR inhibitor AZD2104. <i>Oncogene</i> , 2020, 39, 3507-3521.	2.6	23
106	Effectiveness of PD-1/PD-L1 inhibitors in the treatment of lung cancer: Brightness and challenge. <i>Science China Life Sciences</i> , 2020, 63, 1499-1514.	2.3	20
107	Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA. <i>Journal of Clinical Oncology</i> , 2020, 38, 9501-9501.	0.8	119
108	Phase II study of savolitinib in patients (pts) with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations (METex14+). <i>Journal of Clinical Oncology</i> , 2020, 38, 9519-9519.	0.8	50

#	ARTICLE	IF	CITATIONS
109	Phase III study of tislelizumab plus chemotherapy vs chemotherapy alone as first-line (1L) treatment for advanced squamous non-small cell lung cancer (sq NSCLC).. Journal of Clinical Oncology, 2020, 38, 9554-9554.	0.8	4
110	A phase I study to evaluate safety, tolerability, pharmacokinetics, and preliminary antitumor activity of TQ-B3101.. Journal of Clinical Oncology, 2020, 38, e21705-e21705.	0.8	7
111	366â€¦A randomized double-blind placebo-controlled phase III study evaluating perioperative toripalimab combined with platinum-based doublet chemotherapy in resectable stage III NSCLC. , 2020, , .		0
112	<p>Intercalated combination of chemotherapy and erlotinib for stage IIIA non-small-cell lung cancer: a multicenter, open-label, single-arm, phase II study</p>. Cancer Management and Research, 2019, Volume 11, 6543-6552.	0.9	4
113	The Diversity of Gut Microbiome is Associated With Favorable Responses to Antiâ€“Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC. Journal of Thoracic Oncology, 2019, 14, 1378-1389.	0.5	310
114	Î²Klotho is identified as a target for theranostics in non-small cell lung cancer. Theranostics, 2019, 9, 7474-7489.	4.6	11
115	Liquid biopsy-based single-cell metabolic phenotyping of lung cancer patients for informative diagnostics. Nature Communications, 2019, 10, 3856.	5.8	37
116	Reciprocal regulatory mechanism between miR-214-3p and FGFR1 in FGFR1-amplified lung cancer. Oncogenesis, 2019, 8, 50.	2.1	41
117	<p>Response and acquired resistance to savolitinib in a patient with pulmonary sarcomatoid carcinoma harboring MET exon 14 skipping mutation: a case report</p>. OncoTargets and Therapy, 2019, Volume 12, 7323-7328.	1.0	19
118	Durable Clinical Response of Lung Adenocarcinoma Harboring EGFR 19Del/T790M/in trans-C797S to Combination Therapy of First- and Third-Generation EGFR Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology, 2019, 14, e157-e159.	0.5	24
119	Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors. Oncologist, 2019, 24, S21-S30.	1.9	22
120	Immunoâ€“Oncology in China. Oncologist, 2019, 24, S1-S2.	1.9	0
121	Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology. Cancer Biology and Medicine, 2019, 16, 189.	1.4	16
122	The PI3K inhibitor buparlisib suppresses osteoclast formation and tumour cell growth in bone metastasis of lung cancer, as evidenced by multimodality molecular imaging. Oncology Reports, 2019, 41, 2636-2646.	1.2	10
123	<p>Development of treatment options for Chinese patients with advanced squamous cell lung cancer: focus on afatinib</p>. OncoTargets and Therapy, 2019, Volume 12, 1521-1538.	1.0	3
124	Value of folate receptor-positive circulating tumour cells in the clinical management of indeterminate lung nodules: A non-invasive biomarker for predicting malignancy and tumour invasiveness. EBioMedicine, 2019, 41, 236-243.	2.7	38
125	MiR-516a-5p inhibits the proliferation of non-small cell lung cancer by targeting HIST3H2A. International Journal of Immunopathology and Pharmacology, 2019, 33, 205873841984148.	1.0	14
126	Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer. Lung Cancer, 2019, 132, 126-131.	0.9	26

#	ARTICLE	IF	CITATIONS
127	Exosomal miR-499a-5p promotes cell proliferation, migration and EMT via mTOR signaling pathway in lung adenocarcinoma. <i>Experimental Cell Research</i> , 2019, 379, 203-213.	1.2	79
128	Rethinking Our Approach of Combining Novel Agents With Standard Chemotherapy in Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 580-582.	0.5	1
129	Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. <i>Lancet, The</i> , 2019, 393, 1819-1830.	6.3	2,347
130	Comparison of genomic landscapes of large cell neuroendocrine carcinoma, small cell lung carcinoma, and large cell carcinoma. <i>Thoracic Cancer</i> , 2019, 10, 839-847.	0.8	23
131	EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 732-736.	0.5	40
132	Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial. <i>Journal of Thoracic Oncology</i> , 2019, 14, 867-875.	0.5	260
133	Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study. <i>Lung Cancer</i> , 2019, 130, 18-24.	0.9	10
134	First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1569-1579.	1.2	31
135	Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, 989-999.	1.3	28
136	Long-term efficacy of afatinib in a patient with squamous cell carcinoma of the lung and multiple ERBB family aberrations. <i>Anti-Cancer Drugs</i> , 2019, 30, 873-878.	0.7	6
137	Distribution of NRG1 Gene Fusions in a Large Population of Chinese Patients with NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, e263-e266.	0.5	6
138	FGA isoform as an indicator of targeted therapy for EGFR mutated lung adenocarcinoma. <i>Journal of Molecular Medicine</i> , 2019, 97, 1657-1668.	1.7	7
139	Prognostic significance of anaplastic lymphoma kinase rearrangement in patients with completely resected lung adenocarcinoma. <i>Journal of Thoracic Disease</i> , 2019, 11, 4258-4270.	0.6	11
140	Lung squamous cell carcinoma: A postoperative recurrence analysis of keratinizing and nonkeratinizing subtypes. <i>European Journal of Surgical Oncology</i> , 2019, 45, 838-844.	0.5	6
141	PD-1 blockade augments humoral immunity through ICOS-mediated CD4+ T cell instruction. <i>International Immunopharmacology</i> , 2019, 66, 127-138.	1.7	18
142	Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 127, 19-24.	0.9	41
143	The cis compound EGFR mutations in Chinese advanced non-small cell lung cancer patients. <i>Cancer Biology and Therapy</i> , 2019, 20, 1097-1104.	1.5	13
144	Crizotinib versus pemetrexed-based chemotherapy in patients with advanced ROS1-rearranged non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9101-9101.	0.8	2

#	ARTICLE	IF	CITATIONS
145	CANOPY-A: A phase III study of canakinumab as adjuvant therapy in patients with surgically resected non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2019, 37, TPS8570-TPS8570.	0.8	6
146	The CANOPY program: Canakinumab in patients (pts) with non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2019, 37, TPS9124-TPS9124.	0.8	11
147	Prevalence of MET exon 14 skipping mutation in pulmonary sarcomatoid carcinoma patients without common targetable mutations: A single-institute study. Journal of Cancer Research and Therapeutics, 2019, 15, 909.	0.3	14
148	Development and validation of a deep learning model to assess tumor progression to immunotherapy.. Journal of Clinical Oncology, 2019, 37, e20601-e20601.	0.8	3
149	Efficacy and safety of IBI305 compared with bevacizumab in advanced non-squamous NSCLC patients as first-line treatment in a randomized, double-blind, phase III study.. Journal of Clinical Oncology, 2019, 37, 9095-9095.	0.8	0
150	Inhibiting proliferation and migration of lung cancer using small interfering RNA targeting on Aldo-keto reductase family 1 member B10. Molecular Medicine Reports, 2018, 17, 2153-2160.	1.1	10
151	The Hippo/YAP1 pathway interacts with FGFR1 signaling to maintain stemness in lung cancer. Cancer Letters, 2018, 423, 36-46.	3.2	52
152	Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6). Patient, 2018, 11, 131-141.	1.1	20
153	Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2018, 36, 1405-1411.	0.8	230
154	Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Fruquintinib After Two Prior Chemotherapy Regimens in Chinese Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2018, 36, 1207-1217.	0.8	23
155	A Randomized Controlled Study of rhTPO and rhIL-11 for the Prophylactic Treatment of Chemotherapy-Induced Thrombocytopenia in Non-Small Cell Lung Cancer. Journal of Cancer, 2018, 9, 4718-4725.	1.2	10
156	Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial. OncoTargets and Therapy, 2018, Volume 11, 8575-8587.	1.0	21
157	Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung. OncoTargets and Therapy, 2018, Volume 11, 8565-8573.	1.0	8
158	Characterization of drug responses of mini patient-derived xenografts in mice for predicting cancer patient clinical therapeutic response. Cancer Communications, 2018, 38, 1-12.	3.7	57
159	Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies. Lung Cancer, 2018, 126, 1-8.	0.9	40
160	Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China. PLoS ONE, 2018, 13, e0205827.	1.1	23
161	Nedaplatin Plus Docetaxel Versus Cisplatin Plus Docetaxel as First-Line Chemotherapy for Advanced Squamous Cell Carcinoma of the Lung: A Multicenter, Open-label, Randomized, Phase III Trial. Journal of Thoracic Oncology, 2018, 13, 1743-1749.	0.5	13
162	Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 987-995.	0.5	67

#	ARTICLE	IF	CITATIONS
163	FGFR1-ERK1/2-SOX2 axis promotes cell proliferation, epithelialâ€mesenchymal transition, and metastasis in FGFR1-amplified lung cancer. <i>Oncogene</i> , 2018, 37, 5340-5354.	2.6	123
164	Next generation sequencing reveals a novel ALK G1128A mutation resistant to crizotinib in an ALK-Rearranged NSCLC patient. <i>Lung Cancer</i> , 2018, 123, 83-86.	0.9	19
165	Bexarotene inhibits the viability of non-small cell lung cancer cells via slc10a2/PPARÎ³/PTEN/mTOR signaling pathway. <i>BMC Cancer</i> , 2018, 18, 407.	1.1	33
166	Xenograft tumors derived from malignant pleural effusion of the patients with nonâ€smallâ€cell lung cancer as models to explore drug resistance. <i>Cancer Communications</i> , 2018, 38, 1-12.	3.7	14
167	Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Nonâ€Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1539-1548.	0.5	146
168	A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with KRAS mutation: JUNIPER.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9025-9025.	0.8	23
169	A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel. <i>Translational Lung Cancer Research</i> , 2018, 7, 428-436.	1.3	7
170	Mutation profiling and treatment choosing of Chinese ROS1 positive advanced lung cancer patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21102-e21102.	0.8	1
171	High-throughput screening of rare metabolically active tumor cells in pleural effusion and peripheral blood of lung cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 2544-2549.	3.3	67
172	A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel. <i>ESMO Open</i> , 2017, 2, e000174.	2.0	3
173	Genome-wide DNA Methylation Analysis Reveals GABBR2 as a Novel Epigenetic Target for EGFR 19 Deletion Lung Adenocarcinoma with Induction Erlotinib Treatment. <i>Clinical Cancer Research</i> , 2017, 23, 5003-5014.	3.2	16
174	FGF2/FGFR1 regulates autophagy in FGFR1-amplified non-small cell lung cancer cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 72.	3.5	50
175	Evaluation of the VeriStrat Â® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study. <i>Lung Cancer</i> , 2017, 109, 101-108.	0.9	25
176	EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6. <i>British Journal of Cancer</i> , 2017, 116, 175-185.	2.9	76
177	Integrated discovery of FOXO1â€DNA stabilizers from marine natural products to restore chemosensitivity to anti-EGFR-based therapy for metastatic lung cancer. <i>Molecular BioSystems</i> , 2017, 13, 330-337.	2.9	8
178	Correlation of clinicopathologic features and lung squamous cell carcinoma subtypes according to the 2015 WHO classification. <i>European Journal of Surgical Oncology</i> , 2017, 43, 2308-2314.	0.5	13
179	Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status. <i>Scientific Reports</i> , 2017, 7, 8483.	1.6	6
180	Assessment of interfering factors and clinical risk associated with discontinuation of pemetrexed maintenance therapy in advanced non-squamous non-small cell lung cancer. <i>Lung Cancer</i> , 2017, 111, 43-50.	0.9	2

#	ARTICLE	IF	CITATIONS
181	Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China. <i>Oncotarget</i> , 2017, 8, 9996-10006.	0.8	47
182	Clinic application of tissue engineered bronchus for lung cancer treatment. <i>Journal of Thoracic Disease</i> , 2017, 9, 22-29.	0.6	18
183	Tumor invasiveness defined by IASLC/ATS/ERS classification of ground-glass nodules can be predicted by quantitative CT parameters. <i>Journal of Thoracic Disease</i> , 2017, 9, 1190-1200.	0.6	36
184	Design and implementation of a mobile system for lung cancer patient follow-up in China and initial report of the ongoing patient registry. <i>Oncotarget</i> , 2017, 8, 5487-5497.	0.8	11
185	Efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in targeted therapy of lung squamous cell carcinoma patients with EGFR mutation: a pooled analysis. <i>Oncotarget</i> , 2017, 8, 53675-53683.	0.8	9
186	A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer. <i>Oncotarget</i> , 2017, 8, 41474-41486.	0.8	13
187	Endostar in combination with postoperative adjuvant chemotherapy prolongs the disease free survival of stage IIIA NSCLC patients with high VEGF expression. <i>Oncotarget</i> , 2017, 8, 79703-79711.	0.8	2
188	Differential crizotinib efficacy among ROS1 fusion partners in ROS1-positive non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9067-9067.	0.8	1
189	Phase III study of NEPA, a fixed combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV).. <i>Journal of Clinical Oncology</i> , 2017, 35, 10090-10090.	0.8	1
190	Association of circulating tumor DNA clearance during treatment with improved progression-free survival in advanced non-small cell lung cancer patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11528-11528.	0.8	0
191	XBP1-LOX Axis is critical in ER stress-induced growth of lung adenocarcinoma in 3D culture. <i>American Journal of Translational Research (discontinued)</i> , 2017, 9, 700-707.	0.0	6
192	SIRT2 inhibits non-small cell lung cancer cell growth through impairing Skp2-mediated p27 degradation. <i>Oncotarget</i> , 2016, 7, 18927-18939.	0.8	33
193	A novel paclitaxel-loaded poly(D,L-lactide-co-glycolide)-Tween 80 copolymer nanoparticle overcoming multidrug resistance for lung cancer treatment. <i>International Journal of Nanomedicine</i> , 2016, 11, 2119.	3.3	17
194	FGFR1 promotes the stem cell-like phenotype of FGFR1-amplified non-small cell lung cancer cells through the Hedgehog pathway. <i>Oncotarget</i> , 2016, 7, 15118-15134.	0.8	42
195	Identification of FGF19 as a prognostic marker and potential driver gene of lung squamous cell carcinomas in Chinese smoking patients. <i>Oncotarget</i> , 2016, 7, 18394-18402.	0.8	38
196	An East Asian subgroup analysis of PROCLAIM, a phase III trial of pemetrexed and cisplatin or etoposide and cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-“small cell lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, 380-387.	0.7	5
197	Frequencies of ALK rearrangements in lung adenocarcinoma subtypes: a study of 2299 Chinese cases. <i>SpringerPlus</i> , 2016, 5, 894.	1.2	14
198	Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. <i>Lancet Oncology</i> , The, 2016, 17, 577-589.	5.1	950

#	ARTICLE	IF	CITATIONS
199	Prognostic value of MMP9 activity level in resected stage I B lung adenocarcinoma. <i>Cancer Medicine</i> , 2016, 5, 2323-2331.	1.3	11
200	Meta-Analysis of First-Line Pemetrexed Plus Platinum Treatment in Compared to Other Platinum-Based Doublet Regimens in Elderly East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2016, 17, e103-e112.	1.1	11
201	Economic analysis of <i>ALK</i> testing and crizotinib therapy for advanced non-small-cell lung cancer. <i>Pharmacogenomics</i> , 2016, 17, 985-994.	0.6	22
202	Different roles of myofibroblasts in the tumorigenesis of nonsmall cell lung cancer. <i>Tumor Biology</i> , 2016, 37, 15525-15534.	0.8	2
203	Phase II study of crizotinib in east Asian patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9022-9022.	0.8	14
204	First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm+) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9046-9046.	0.8	11
205	Phase 3 study of first-line crizotinib vs pemetrexed+cisplatin/carboplatin (PCC) in East Asian patients (pts) with <i>ALK</i> + advanced non-squamous non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9058-9058.	0.8	7
206	Integrated In Silico-In Vitro Discovery of Lung Cancer-related Tumor Pyruvate Kinase M2 (PKM2) Inhibitors. <i>Medicinal Chemistry</i> , 2016, 12, 613-620.	0.7	14
207	Genome-wide screen of DNA methylation study in stage IIIa (N2) EGFR 19 deletion adenocarcinoma with erlotinib treatment.. <i>Journal of Clinical Oncology</i> , 2016, 34, e20067-e20067.	0.8	0
208	A Multicenter, Open-Label, Randomized Phase II Controlled Study of rh-Endostatin (Endostar) in Combination with Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 206-211.	0.5	39
209	Transforming growth factor- β 21-induced epithelial to mesenchymal transition increases mitochondrial content in the A549 non-small cell lung cancer cell line. <i>Molecular Medicine Reports</i> , 2015, 11, 417-421.	1.1	13
210	Isolation and characterization of ex vivo expanded mesenchymal stem cells obtained from a surgical patient. <i>Molecular Medicine Reports</i> , 2015, 11, 1777-1783.	1.1	3
211	Detection and correlation analysis of serum cytokines in non-small-cell lung cancer patients with bone and non-bone metastases. <i>Patient Preference and Adherence</i> , 2015, 9, 1165.	0.8	7
212	BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 2197-2204.	0.8	323
213	Clinical analysis of 95 cases of pulmonary sarcomatoid carcinoma. <i>Biomedicine and Pharmacotherapy</i> , 2015, 76, 134-140.	2.5	41
214	Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. <i>Lancet Oncology</i> , The, 2015, 16, 141-151.	5.1	1,369
215	TERT Polymorphism rs2736100-C Is Associated with EGFR Mutation-Positive Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 5173-5180.	3.2	47
216	SEMA4B inhibits growth of non-small cell lung cancer in vitro and in vivo. <i>Cellular Signalling</i> , 2015, 27, 1208-1213.	1.7	51

#	ARTICLE	IF	CITATIONS
217	An interaction map of small-molecule kinase inhibitors with anaplastic lymphoma kinase (ALK) mutants in ALK-positive non-small cell lung cancer. <i>Biochimie</i> , 2015, 112, 111-120.	1.3	22
218	Maintenance Therapy Improves Survival Outcomes in Patients with Advanced Non-small Cell Lung Cancer: A Meta-analysis of 14 Studies. <i>Lung</i> , 2015, 193, 805-814.	1.4	13
219	NF- κ B-mediated miR-124 suppresses metastasis of non-small-cell lung cancer by targeting MYO10. <i>Oncotarget</i> , 2015, 6, 8244-8254.	0.8	73
220	A survival comparison study of Chinese patients with primary lung adenocarcinoma harboring ALK rearrangements with crizotinib treatment detected by FISH, IHC, and RT-PCR.. <i>Journal of Clinical Oncology</i> , 2015, 33, e19135-e19135.	0.8	1
221	Effect of intercalated erlotinib with gemcitabine/cisplatin as neoadjuvant treatment in stage IIIA unresectable non-small cell lung cancer (CTONG 1101, NCT01297101) on disease-free survival: A single arm, multi-center, phase II study.. <i>Journal of Clinical Oncology</i> , 2015, 33, e18519-e18519.	0.8	0
222	Inhibition of the growth of non-small cell lung cancer by miRNA-1271. <i>American Journal of Translational Research (discontinued)</i> , 2015, 7, 1917-24.	0.0	13
223	Role of WNT1-inducible-signaling pathway protein 1 in etoposide resistance in lung adenocarcinoma A549 cells. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 14962-8.	1.3	0
224	Regulation of β -catenin-mediated esophageal cancer growth and invasion by miR-214. <i>American Journal of Translational Research (discontinued)</i> , 2015, 7, 2316-25.	0.0	11
225	The predictive role of pretreatment epidermal growth factor receptor T790M mutation on the progression-free survival of tyrosine-kinase inhibitor-treated non-small cell lung cancer patients: a meta-analysis. <i>OncoTargets and Therapy</i> , 2014, 7, 387.	1.0	24
226	Everolimus and zoledronic acid—a potential synergistic treatment for lung adenocarcinoma bone metastasis. <i>Acta Biochimica Et Biophysica Sinica</i> , 2014, 46, 792-801.	0.9	12
227	FBXL5-mediated degradation of single-stranded DNA-binding protein hSSB1 controls DNA damage response. <i>Nucleic Acids Research</i> , 2014, 42, 11560-11569.	6.5	30
228	Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 213-222.	5.1	1,740
229	Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer. <i>Lung Cancer</i> , 2014, 85, 401-407.	0.9	31
230	The polycomb group protein EZH2 inhibits lung cancer cell growth by repressing the transcription factor Nrf2. <i>FEBS Letters</i> , 2014, 588, 3000-3007.	1.3	47
231	Continuation of afatinib beyond progression: Results of a randomized, open-label, phase III trial of afatinib plus paclitaxel (P) versus investigator's choice chemotherapy (CT) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) progressed on erlotinib/gefitinib (E/G) and afatinib's LUX-Lung 5 (L5).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8019-8019.	0.8	21
232	Molecular epidemiology of EGFR mutations in 7,953 non-small cell lung cancer of Chinese ethnicity.. <i>Journal of Clinical Oncology</i> , 2014, 32, e19009-e19009.	0.8	1
233	Acetylcholine receptor pathway in lung cancer: New twists to an old story. <i>World Journal of Clinical Oncology</i> , 2014, 5, 667.	0.9	23
234	Meta-analysis for curative effect of lobectomy and segmentectomy on non-small cell lung cancer. <i>International Journal of Clinical and Experimental Medicine</i> , 2014, 7, 2599-604.	1.3	8

#	ARTICLE	IF	CITATIONS
235	Formononetin suppresses the proliferation of human non-small cell lung cancer through induction of cell cycle arrest and apoptosis. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 8453-61.	0.5	24
236	Prognostic Significance of the Extent of Lymph Node Involvement in Stage II-N1 Non-small Cell Lung Cancer. <i>Chest</i> , 2013, 144, 1253-1260.	0.4	25
237	LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8016-8016.	0.8	44
238	Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with <i>EGFR</i> mutation-positive advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 7520-7520.	0.8	40
239	Randomized phase II study of recombinant human endostatin in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer (NCT00912392).. <i>Journal of Clinical Oncology</i> , 2012, 30, 7091-7091.	0.8	0
240	Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2011, 12, 735-742.	5.1	3,758
241	Maintenance therapy for NSCLC: Consensus and controversy. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2011, 23, 254-258.	0.7	6
242	Sirtuin expression is downregulated in non-small cell lung cancer. <i>FASEB Journal</i> , 2010, 24, 567.3.	0.2	0
243	Perioperative chemotherapy of stage III N2 non-small cell lung cancer. <i>Chinese-German Journal of Clinical Oncology</i> , 2009, 8, 185-189.	0.1	0
244	The effects of cetuximab alone and in combination with endostatin on vascular endothelial growth factor and interleukin-8 expression in human lung adenocarcinoma cells. <i>Current Therapeutic Research</i> , 2009, 70, 116-128.	0.5	8
245	Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice. <i>Oncology Reports</i> , 2008, 20, 581-7.	1.2	24
246	The relationship between the pathological changes and response rate (RR) in non-small cell lung cancer treated by neoadjuvant chemotherapy with mitomycin (MMC), vindesine (VDS) and cisplatin (DDP) combination. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2000, 12, 220-223.	0.7	0